Why the study?
Do GLP-1 receptor agonists exenatide and liraglutide reduce SBP and DBP in patients with T2DM?
Do GLP-1 receptor agonists exenatide and liraglutide reduce SBP and DBP in patients with T2DM?
GLP-1 receptor agonists exenatide and liraglutide modestly reduce blood pressure by 1 to 5 mmHg in patients with type 2 diabetes, which may provide additional cardiovascular benefits.
Modest BP reductions may add CV benefit in T2DM; confirms class effect in Level 1 evidence.
Treatment with the GLP-1 RAs exenatide and liraglutide reduced SBP and DBP by 1 to 5 mmHg compared with some other anti-diabetic drugs including insulin, glimepiride and placebo for patients with T2DM. GLP-1 RAs may offer an alternative therapy for these patients and will help provide extra cardiovascular benefits.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: